Emla cream 30 g — Made in UK — Free Delivery

Product description

Emla cream is used for surface anesthesia of the skin at the injection site.

Structure

Active ingredients: lidocaine, prilocaine;

1 g of cream contains lidocaine 25 mg prilocaine 25 mg;

Excipients: castor oil polyethoxylated, hydrogenated carbomer 974 R, sodium hydroxide, purified water.

Contraindications

Hypersensitivity to local anesthetics of a group of substituted amides such as bupivacaine, etidocaine, mepivacaine or any of the excipients. Violation of the integrity of the skin at the site of application of the cream (active herpes zoster, atopic dermatitis or wounds).

Mode of application

Apply before administering local anesthetics:

men - 1 g per 10 cm 2; the cream is applied to the skin in a thick layer;

application duration - 15 minutes;

women - 1-2 g per 10 cm 2; the cream is applied to the skin in a thick layer;

the duration of the application is 60 minutes.

Application features

Pregnant

For short-term use during pregnancy, the benefits are considered to outweigh the potential risks.

Children

The cream is used for children from birth.

Drivers

Does not affect.

Overdose

With the possible occurrence of toxic effects, it is expected that the symptoms will be similar to those of treatment with other local anesthetics, that is, excitation of the central nervous system, and in severe cases, depression of the central nervous system and myocardial activity.

Possibly increased sweating, pallor of the skin, dizziness, headache, blurred vision, tinnitus, diplopia, decreased blood pressure, bradycardia, arrhythmia, drowsiness, chills, numbness of the limbs, anxiety, convulsions, shock, cardiac arrest.

When the first signs of intoxication appear (dizziness, nausea, vomiting, euphoria), transfer the patient to a horizontal position; prescribe oxygen inhalation; with bradycardia - M-anticholinergics (atropine), vasoconstrictors (norepinephrine, phenylephrine).

Side effects

On the part of the skin and subcutaneous tissue: Temporary reactions at the site of application, such as pallor, redness, edema. In the first minutes after application, mild burning, itching or heat at the site of application.

Interaction

Emla can increase the formation of methemoglobin in patients taking certain preparations that promote the formation of methemoglobin (for example, sulfonamides).

When using large doses of the preparation Emla, one should take into account the risk of developing an additive effect in patients using local anesthetics or preparations that are structurally similar to the latter, for example tokinide.

Storage conditions

Store at a temperature not exceeding 30 ° C. Do not freeze.

Keep out of the reach of children.

Shelf life is 3 years.